Antibodies against ARHGDIB and ARHGDIB gene expression associate with kidney allograft outcome

**METHODS**

*Case – control study*

- 203 Patients with ABMR histology
- 219 Patients without ABMR histology

**13 NON-HLA ANTIBODIES:**

- Anti - Agrin
- Anti - APMAP
- Anti - ARHGDB
- Anti - ARHGEF6
- Anti - AT1R
- Anti - ETAR
- Anti - LMNB1
- Anti - LPLUNC1
- Anti - PECR
- Anti - PLA2R
- Anti - PRKCB
- Anti - TUBB4b
- Anti - Vimentin

**ASSOCIATION WITH GRAFT SURVIVAL**

*Anti-ARHGDIB antibodies ≥ 2000 MFI*

- 10 years survival:
  - No antibodies → 86.2%
  - HLA-DSA → 58.1%
  - Anti-ARHGDIB → 47.6%
  - Anti-ARHGDIB + HLA-DSA → 25.0%

**ASSOCIATION WITH ABMR\(_h\)**

*(Banff criteria 1 and 2)*

- Non-HLA status:
  - Occurrence of ABMR\(_h\): p value > 0.05

- Patients with non-HLA antibodies:
  - p value < 0.0001

Senev et al. *Transplantation*. September 2019

@TransplantJrnl